AGCT1532 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Brief description of study

The purpose of this study is to investigate the accelerated BEP in improving the safety and efficacy for patients with intermediate and poor-risk metastatic germ cell tumours. We want to know if accelerated BEP is superior to standard BEP.

We are using study drugs Ifosfamide, Cisplatin, Pegfilgrastim, Etoposide, Bleomycin, MESNA and Filgrastim to determine progression- free survival, adverse events, and health-related quality of life.


Clinical Study Identifier: s22-00117
ClinicalTrials.gov Identifier: NCT02582697
Principal Investigator: Sharon L Gardner.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.